{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-188075","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2025-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.328118+00:00","generated_at":"2026-05-17T09:53:24.849540+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Plus Therapeutics regains Nasdaq compliance on two listing rules; bid price deadline extended to Nov 12, 2025","bullets":["Nasdaq confirmed compliance with MVLS ($35M) and equity ($2.5M) standards on Aug 22, 2025.","Bid price rule deadline extended to Nov 12, 2025; prior Sept 8 deadline no longer applies.","One-year monitoring for equity standard through Aug 22, 2026; breach triggers delist process without cure period.","Company now satisfies two alternative criteria under Nasdaq Listing Rule 5550."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-188075","json":"https://secwatch.observer/filing/0001193125-25-188075.json","markdown":"https://secwatch.observer/filing/0001193125-25-188075.md","text":"https://secwatch.observer/filing/0001193125-25-188075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312525188075/0001193125-25-188075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312525188075/d919644d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:53:24.849540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}